Paul Dransfield

Paul Dransfield serves as the Senior Director of Medicinal Chemistry at Delphia Therapeutics since April 2025, following a tenure as Director of Medicinal Chemistry at Frontier Medicines from January 2023 to February 2025, and Head of Medicinal Chemistry at Theonys for a brief period in late 2022. Prior to these roles, Paul held various positions at H3 Biomedicine, culminating as Executive Director where leadership in medicinal chemistry efforts focused on developing chemical matter across diverse therapeutic targets. Paul also contributed significantly at Amgen over 15 years, progressing from Scientist to Principal Scientist, leading teams to successful outcomes in neuroscience and other initiatives. Academic qualifications include a Postdoctoral degree in Organic Chemistry from Texas A&M University, a Ph.D. in Organic Chemistry from the University of Exeter, and a Master's degree in Chemistry, also from the University of Exeter.